RegenXBio Inc. (RGNX) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RegenXBio Inc. (RGNX) is running a late stage study of RGX-121, a gene therapy for children with neuronopathic MPS II, also known as Hunter Syndrome. The Phase 3 trial aims to see if a single treatment can improve symptoms, slow disease progression in the brain, and offer a longer term alternative to current supportive care.
The treatment being tested is RGX-121-3102, a genetic medicine delivered by an AAV9 viral vector. It is designed to provide a working copy of the IDS gene directly to the central nervous system so patients can produce the missing enzyme instead of relying on repeated infusions.
The study uses a single group, open label design, so every child enrolled receives RGX-121 at a dose set per brain mass. There is no placebo arm, and the main focus is treatment benefit, with researchers tracking safety, clinical outcomes, and how the body responds to different dose levels.
The trial is listed as Phase 3 and interventional, but its status is currently suspended, meaning new activity is on hold for now. The record was last updated on February 25, 2026, which matters because it shows regulators and the company are actively maintaining the listing and signals recent changes that investors should note.
This update is important for RGNX because RGX-121 targets a rare disease where even modest progress can support premium pricing and potential partnerships. A suspended status, however, can pressure the stock in the short term, raise questions on safety, design, or strategy, and may benefit competing gene therapy players working on lysosomal storage disorders.
Investors will watch closely for clarity on the reason for the suspension, any regulatory feedback, and updated timelines, as a return to active status could restore confidence. Until then, sentiment around RGNX may stay cautious, with valuation more tied to the broader gene therapy pipeline and sector risk appetite than to this single program.
The RGX-121 Phase 3 study remains listed as an active record with a recent update, and more information is available on the ClinicalTrials portal.
To learn more about RGNX’s potential, visit the RegenXBio Inc. drug pipeline page.